PharmacoEconomics

An Overview of Methods and Applications to Value Informal Care in Economic Evaluations of Healthcare
pp. 269-280(12)
Authors: Koopmanschap, Marc A.; van Exel, N. Job A.; Bernard van den Berg,; Brouwer, Werner B.F.

Making a Case for Employing a Societal Perspective in the Evaluation of Medicaid Prescription Drug Interventions
pp. 281-296(16)
Authors: Roy, Sanjoy; Madhavan, S. Suresh

The Use of QALY Weights for QALY Calculations: A Review of Industry Submissions Requesting Listing on the Australian Pharmaceutical Benefits Scheme 2002-4
pp. 297-310(14)
Authors: Scuffham, Paul A.; Whitty, Jennifer A.; Mitchell, Andrew; Viney, Rosalie

Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related Osteoporosis: Cost-Utility Analysis Using a Markov Model
pp. 311-328(18)
Authors: Kreck, Simon; Klaus, Jochen; Leidl, Reiner; Christian von Tirpitz,; Konnopka, Alexander; Matschinger, Herbert; König, Hans-Helmut

An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes
pp. 329-339(11)
Authors: Ramsey, Scott D.; Clarke, Lauren D.; Roberts, Craig S.; Sullivan, Sean D.; Johnson, Scott J.; Liu, Larry Z.

Cost-Utility Analysis of Treatment with Olanzapine Compared with Other Antipsychotic Treatments in Patients with Schizophrenia in the Pan-European SOHO Study
pp. 341-358(18)
Authors: Knapp, Martin; Windmeijer, Frank; Brown, Jacqueline; Kontodimas, Stathis; Tzivelekis, Spyridon; Josep Maria Haro,; Ratcliffe, Mark; Hong, Jihyung; Novick, Diego